G racell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company aims …
( read original story …)
The Shanghai News
G racell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company aims …
( read original story …)